
News|Articles|June 1, 2010
FDA Pipeline Preview, June 2010 (BMS-224818, Roflumilast, Prostvac, Naltrexone, IL13-PE38QQR/IL13-PE, Prochymal, AEZS-108, SBC-102, Pralatrexate, RG2833)
Recent FDA action (through, May 2010) related to BMS-224818, Roflumilast, Prostvac, Naltrexone, IL13-PE38QQR/IL13-PE, Prochymal, AEZS-108, SBC-102, Pralatrexate, RG2833
Advertisement
Complete reponse
Fast-track designation
Priority review
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Advancing Equity and Access in Breast Cancer Care
2
Aflibercept 8 mg Shows Promise in Reducing Injection Burden | AAO 2025
3
Obesity Is Now Also a Problem for People With Type 1 Diabetes
4
Data From Two Rebyota Trials Show Quality of Life Improvements | IDWeek 2025
5